A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
Bai Liu(Altor BioScience (United States)), Hing C. Wong(Altor BioScience (United States))
Cited by 79
Related Papers
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
|Journal of Clinical Investigation|2017|311
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas
|Clinical Cancer Research|2015|147